Published in J Gen Virol on March 01, 1999
Foot-and-mouth disease. Clin Microbiol Rev (2004) 4.34
Induction of foot-and-mouth disease virus-specific cytotoxic T cell killing by vaccination. Clin Vaccine Immunol (2010) 0.96
Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J Virol (2000) 0.87
Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. Virol J (2013) 0.87
Promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type O in swine. Clin Vaccine Immunol (2010) 0.80
A pseudotype baculovirus expressing the capsid protein of foot-and-mouth disease virus and a T-cell immunogen shows enhanced immunogenicity in mice. Virol J (2011) 0.80
Characterization of cytotoxic T lymphocyte function after foot-and-mouth disease virus infection and vaccination. Viral Immunol (2013) 0.76
A Recombinant Adenovirus Expressing P12A and 3C Protein of the Type O Foot-and-Mouth Disease Virus Stimulates Systemic and Mucosal Immune Responses in Mice. Biomed Res Int (2016) 0.75
The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance--a review. Gene (1985) 3.42
Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology (1983) 3.04
Foot-and-mouth disease virus leader proteinase: purification of the Lb form and determination of its cleavage site on eIF-4 gamma. J Virol (1994) 2.41
Ultra-low dose intravenous heparin in the prevention of postoperative deep-vein thrombosis. Lancet (1980) 2.20
Fitness alteration of foot-and-mouth disease virus mutants: measurement of adaptability of viral quasispecies. J Virol (1991) 1.89
Establishment of cell lines persistently infected with foot-and-mouth disease virus. Virology (1985) 1.84
Spontaneous external biliary fistula uncomplicated by gallstones. Postgrad Med J (1991) 1.76
Evolution of the capsid protein genes of foot-and-mouth disease virus: antigenic variation without accumulation of amino acid substitutions over six decades. J Virol (1992) 1.72
Implications of a quasispecies genome structure: effect of frequent, naturally occurring amino acid substitutions on the antigenicity of foot-and-mouth disease virus. Proc Natl Acad Sci U S A (1989) 1.71
Foot-and-mouth disease virus: a long known virus, but a current threat. Vet Res (2001) 1.70
Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear translocation in human lymphocytes. J Biol Chem (1999) 1.59
Synthetic peptide vaccine confers protection against murine malaria. J Exp Med (1987) 1.58
A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C. J Gen Virol (1990) 1.57
Fixation of mutations in the viral genome during an outbreak of foot-and-mouth disease: heterogeneity and rate variations. Gene (1986) 1.53
Difference in glucose sensitivity of liver glycolysis and glycogen synthesis. Relationship between lactate production and fructose 2,6-bisphosphate concentration. Biochem J (1984) 1.49
Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J Exp Med (1999) 1.45
Two-dimensional viscous froth model for foam dynamics. Phys Rev E Stat Nonlin Soft Matter Phys (2004) 1.42
The increase of IFN-gamma production through aging correlates with the expanded CD8(+high)CD28(-)CD57(+) subpopulation. Clin Immunol (2000) 1.40
Protein-losing enteropathy in primary lymphoedema: mesenteric lymphography and gut resection. Br J Surg (1974) 1.39
Verapamil in major (psychotic) depression. Br J Psychiatry (1991) 1.39
Developmentally regulated, phospholipase C-mediated release of the major surface glycoprotein of amastigotes of Trypanosoma cruzi. J Exp Med (1988) 1.37
A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J Virol (1997) 1.36
Differentiation of infection from vaccination in foot-and-mouth disease by the detection of antibodies to the non-structural proteins 3D, 3AB and 3ABC in ELISA using antigens expressed in baculovirus. Arch Virol (1998) 1.34
A single amino acid substitution in nonstructural protein 3A can mediate adaptation of foot-and-mouth disease virus to the guinea pig. J Virol (2001) 1.29
The ecological cost of sex. Nature (2000) 1.27
Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine (1999) 1.20
Mechanical performance of acrylic bone cements containing different radiopacifying agents. Biomaterials (2002) 1.19
Molecular cloning of African swine fever virus DNA. Virology (1984) 1.17
Design of primers for PCR amplification of highly variable genomes. Comput Appl Biosci (1993) 1.16
Genetic and immunogenic variations among closely related isolates of foot-and-mouth disease virus. Gene (1988) 1.12
New starch-based thermoplastic hydrogels for use as bone cements or drug-delivery carriers. J Mater Sci Mater Med (1998) 1.11
VPg gene amplification correlates with infective particle formation in foot-and-mouth disease virus. J Virol (1992) 1.10
Swine vesicular disease virus. Pathology of the disease and molecular characteristics of the virion. Anim Health Res Rev (2000) 1.08
Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants. J Virol (1991) 1.07
New aspects of the effect of size and size distribution on the setting parameters and mechanical properties of acrylic bone cements. Biomaterials (1996) 1.07
Gene encoding capsid protein VP1 of foot-and-mouth disease virus: a quasispecies model of molecular evolution. Proc Natl Acad Sci U S A (1988) 1.05
Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs. Virology (1999) 1.02
Deletion or substitution of the aphthovirus 3' NCR abrogates infectivity and virus replication. J Gen Virol (2001) 1.01
Infection with foot-and-mouth disease virus results in a rapid reduction of MHC class I surface expression. J Gen Virol (1998) 1.00
Restriction site map of African swine fever virus DNA. Virology (1984) 1.00
Surface modification tailors the characteristics of biomimetic coatings nucleated on starch-based polymers. J Mater Sci Mater Med (1999) 0.99
The role of small ruminants in the epidemiology and transmission of foot-and-mouth disease. Vet J (1999) 0.98
Branching dendrites with resonant membrane: a "sum-over-trips" approach. Biol Cybern (2007) 0.98
Ethnicity, bioethics, and prenatal diagnosis: the amniocentesis decisions of Mexican-origin women and their partners. Am J Public Health (1999) 0.97
Genetic and phenotypic variability during replication of foot-and-mouth disease virus in swine. Virology (1990) 0.96
In vivo analysis of the stability and fitness of variants recovered from foot-and-mouth disease virus quasispecies. J Gen Virol (1998) 0.96
Immunogenicity of non-structural proteins of foot-and-mouth disease virus: differences between infected and vaccinated swine. Arch Virol (1994) 0.95
Further studies on the early protective responses of pigs following immunisation with high potency foot and mouth disease vaccine. Vaccine (2002) 0.95
Comparison of vaccine strains and the virus causing the 1986 foot-and-mouth disease outbreak in Spain: epizootiological analysis. Virus Res (1990) 0.95
Identification of T-cell epitopes in nonstructural proteins of foot-and-mouth disease virus. J Virol (2001) 0.95
Primer design for specific diagnosis by PCR of highly variable RNA viruses: typing of foot-and-mouth disease virus. Virology (1992) 0.95
The application of new techniques to the improved detection of persistently infected cattle after vaccination and contact exposure to foot-and-mouth disease. Vaccine (2005) 0.94
Comparative study of non-invasive force and stress inference methods in tissue. Eur Phys J E Soft Matter (2013) 0.94
Heterotypic lymphoproliferative response in pigs vaccinated with foot-and-mouth disease virus. Involvement of isolated capsid proteins. J Gen Virol (1992) 0.94
Interferon-gamma production in vitro from whole blood of foot-and-mouth disease virus (FMDV) vaccinated and infected cattle after incubation with inactivated FMDV. Vaccine (2005) 0.93
Duration of immunity of a quadrivalent vaccine against respiratory diseases caused by BHV-1, PI3V, BVDV, and BRSV in experimentally infected calves. Prev Vet Med (2004) 0.92
Association of bovine DRB3 alleles with immune response to FMDV peptides and protection against viral challenge. Vaccine (2000) 0.91
Modelling studies to estimate the prevalence of foot-and-mouth disease carriers after reactive vaccination. Proc Biol Sci (2008) 0.90
Antigenic comparison of different foot-and-mouth disease virus types using monoclonal antibodies defining multiple neutralizing epitopes on FMDV A5 subtypes. Virus Res (1989) 0.90
Localization of foot-and-mouth disease virus RNA by in situ hybridization within bovine tissues. Virus Res (1999) 0.90
Cyclosporin A inhibits phorbol ester-induced activation of superoxide production in resident mouse peritoneal macrophages. Biochem J (1989) 0.90
Cloning and characterization of a gene coding for a protein (KAP) associated with the kinetoplast of epimastigotes and amastigotes of Trypanosoma cruzi. Mol Biochem Parasitol (1990) 0.90
Immune recognition of swine vesicular disease virus structural proteins: novel antigenic regions that are not exposed in the capsid. Virology (2000) 0.89
A RT-PCR assay for the differential diagnosis of vesicular viral diseases of swine. J Virol Methods (1998) 0.89
p53 transactivation of the HIV-1 long terminal repeat is blocked by PD 144795, a calcineurin-inhibitor with anti-HIV properties. J Biol Chem (1998) 0.89
A method for determining the position and size of optimal sequence regions for phylogenetic analysis. J Mol Evol (1995) 0.89
Interspecies major histocompatibility complex-restricted Th cell epitope on foot-and-mouth disease virus capsid protein VP4. J Virol (2000) 0.88
Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus. J Virol (2000) 0.88
The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease. Br Vet J (1995) 0.88
The structural protein p54 is essential for African swine fever virus viability. Virus Res (1996) 0.88
NO induces a cGMP-independent release of cytochrome c from mitochondria which precedes caspase 3 activation in insulin producing RINm5F cells. FEBS Lett (1999) 0.88
Dexamethasone inhibits virus production and the secretory IgA response in oesophageal-pharyngeal fluid in cattle persistently infected with foot-and-mouth disease virus. Epidemiol Infect (1997) 0.88
Hormonal regulation of fructose 2,6-bisphosphate levels in epididymal adipose tissue of rat. FEBS Lett (1985) 0.87
Inhibition of tumor growth by histoincompatible cells expressing interleukin-2. Int Immunol (1992) 0.87
Fixation of mutations at the VP1 gene of foot-and-mouth disease virus. Can quasispecies define a transient molecular clock? Gene (1991) 0.86
Antigenic specificity of porcine T cell response against foot-and-mouth disease virus structural proteins: identification of T helper epitopes in VP1. Virology (1994) 0.86
The N-terminal region of the VP1 protein of swine vesicular disease virus contains a neutralization site that arises upon cell attachment and is involved in viral entry. J Virol (2001) 0.86
A porcine CD8+ T cell clone with heterotypic specificity for foot-and-mouth disease virus. J Gen Virol (1996) 0.86
Transient inhibition of foot-and-mouth disease virus infection of BHK-21 cells by antisense oligonucleotides directed against the second functional initiator AUG. Antiviral Res (1993) 0.85
Specific inhibition of aphthovirus infection by RNAs transcribed from both the 5' and the 3' noncoding regions. J Virol (1994) 0.85
Elevated secretion of myeloperoxidase by neutrophils from asthmatic patients: the effect of immunotherapy. J Allergy Clin Immunol (2001) 0.85
Metabolite utilization by isolated embryonic rat hearts in vitro. J Embryol Exp Morphol (1972) 0.85
Evidence that high potency foot-and-mouth disease vaccine inhibits local virus replication and prevents the "carrier" state in sheep. Vaccine (2004) 0.84
A computer program for the design of PCR primers for diagnosis of highly variable genomes. J Virol Methods (1993) 0.84
Sensory changes following stripping of the long saphenous vein. J Cardiovasc Surg (Torino) (1975) 0.83
Antibody to the nonstructural proteins of foot-and-mouth disease virus in vaccinated animals exposed to infection. Vet Q (1998) 0.83
Molecular epidemiology of foot-and-mouth disease virus type O. J Gen Virol (1993) 0.83
Molecular cloning, expression and immunological analysis of the capsid precursor polypeptide (P1) from swine vesicular disease virus. Virus Res (1998) 0.83
Estimates by computer simulation of genetic distances from comparisons of RNAse A mismatch cleavage patterns. J Virol Methods (1993) 0.83
Modulation of the inhibition of respiratory burst in mouse macrophages by cyclosporin A: effect of in vivo treatment, glucocorticoids and the state of activation of cells. Immunology (1991) 0.83
The structure and function of MHC molecules. Possible implications for the control of tumor growth by MHC-restricted T cells. Semin Cancer Biol (1991) 0.83
Evidence for involvement of c-Src in the anti-apoptotic action of nitric oxide in serum-deprived RINm5F cells. Cell Signal (2001) 0.83
Glucocorticoids inhibit fructose 2,6-bisphosphate synthesis in rat thymocytes. Opposite effect of cycloheximide. Biochim Biophys Acta (1991) 0.82
Stereotactic pallidotomy for the treatment of Parkinson's disease. Efficacy and adverse effects at 6 months in 26 patients. Neurology (1998) 0.82
Stable expression of antisense RNAs targeted to the 5' non-coding region confers heterotypic inhibition to foot-and-mouth disease virus infection. J Gen Virol (2003) 0.82